Continuous VenoVenous Hemofiltration CVVH - Part 2
Continuous VenoVenous Hemofiltration CVVH - Part 2

Continuous VenoVenous Hemofiltration CVVH - Part 2

  • Faculty: Program director Joseph Basha, CCP
  • Date: May 27th, 2020 9:00 am
  • CEU’s: 0.7 CEUs
  • Price: $10.5
  • Category 1 SDCE CEU
Buy Course
Course Rating:
(0 Reviews)

Latest Reviews

View All

Course description

Nathan Bedair, CCP and Joe Basha, CCP take a deeper look at Continuous Veno-Venous Hemofiltration and examine the advantages of CVVH over Intermittent Hemodialysis for the removal of pro-inflammatory mediators and the restoration of physiologic homeostasis.

In "Continuous Veno-Venous Hemofiltration (CVVH) - Part 2," Nathan Bedair, CCP, and Joe Basha, CCP, delve deeper into the complex and critical realm of CVVH, highlighting its superiority over Intermittent Hemodialysis in certain clinical settings. This detailed exploration not only offers insights into the operational mechanics of CVVH but also underscores its clinical implications, particularly in managing acute renal failure, fluid overload, and the removal of pro-inflammatory mediators.

The discussion begins with a retrospective look at foundational studies and theoretical underpinnings of hemofiltration, with particular emphasis on the work of Dr. Ronco. It explores the concept of dosing in hemofiltration, suggesting that higher volumes of effluent or ultrafiltration may lead to better survival rates by more effectively removing harmful substances from the bloodstream. This is an important consideration, as the primary goal of CVVH is to restore physiologic homeostasis by closely mimicking the filtration process of healthy kidneys, thereby bridging the gap left by traditional dialysis methods.

Understanding the mechanisms of CVVH is crucial, with diffusion, convection, and adsorption playing key roles. The conversation elucidates these mechanisms, explaining how they contribute to the efficient clearance of solutes and toxins, including those larger molecules often implicated in inflammatory processes. The importance of achieving balance in patient treatment, aiming for homeostasis through meticulous fluid management and the removal of inflammatory mediators, is a recurring theme.

The dialogue also addresses the practical aspects of implementing CVVH, including equipment considerations and the significance of choosing the right filters to maximize therapeutic outcomes. The discussion of sieving coefficients and molecular weight cut-offs provides a deeper understanding of how CVVH filters operate and their capacity to remove specific molecules, further emphasizing the technique's adaptability to the needs of critically ill patients.

A critical comparison of CVVH with Intermittent Hemodialysis highlights the benefits of continuous filtration, especially in unstable patients. CVVH offers more than just renal support; it provides a means to control fluid balance and remove harmful substances in a more physiologically gentle manner, thereby potentially reducing the systemic inflammatory response often seen in critically ill patients.

Moreover, the discussion ventures into the realm of cytokine storms and systemic inflammatory response syndrome (SIRS), conditions where CVVH might offer significant therapeutic advantages. The ability of CVVH to remove large pro-inflammatory mediators, which are not effectively cleared by traditional hemodialysis, could be critical in managing these life-threatening conditions.

The talk further explores innovative adjunct therapies like cytosorb technology, which enhances the removal of inflammatory mediators, showcasing the evolving landscape of hemofiltration and its potential to address complex clinical challenges beyond renal failure. This aligns with the overarching goal of CVVH: to not only support the kidneys but also to mitigate the broader impacts of critical illness on the body.

Ultimately, "Continuous Veno-Venous Hemofiltration - Part 2" provides a comprehensive overview of CVVH, from its theoretical foundations to its practical application in critical care. It highlights the technique's versatility in managing fluid overload, acute renal failure, and inflammatory conditions, underscoring the importance of early intervention and tailored treatment strategies. Through a blend of theoretical knowledge and practical insights, Bedair and Basha illuminate the significant role of CVVH in modern critical care, offering valuable perspectives for clinicians striving to optimize patient outcomes in the face of complex medical challenges.

#perfusion #CVVH #Hemofiltration 

Register and watch for free @ 

Meet Your Instructor

Program director Joseph Basha, CCP

Program director Joseph Basha, CCP

Joseph has been a practicing clinical perfusionist for 40 years. Joseph is the CEO of Houston Extracorporeal Technologies and is the program director of The New Orleans Conference

Read Full Bio